Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America.
Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, United States of America.
PLoS Med. 2019 Nov 5;16(11):e1002941. doi: 10.1371/journal.pmed.1002941. eCollection 2019 Nov.
With governments' increasing efforts to curb opioid prescription use and limit dose below the Centers for Disease Control and Prevention (CDC)-recommended threshold of 90 morphine milligram equivalents per day, little is known about prescription opioid patterns preceding opioid use disorder (OUD) or overdose. This study aimed to determine prescribed opioid fills and dose trajectories in the year before an incident OUD or overdose diagnosis using a 2005-2016 commercial healthcare database.
This cross-sectional study identified individuals aged 18 to 64 years with incident OUD or overdose in the United States. We measured the prevalence of opioid prescription fills and trajectories of opioid morphine equivalent dose (MED) prescribed during the 12-month period before the diagnosis. Of 227,038 adults with incident OUD or overdose, 33.1% were aged 18 to 30 years, 52.9% were males, and 85.0% were metropolitan residents. Half (50.5%) of the patients had a diagnosis of chronic pain, 32.7% had depression, and 20.3% had anxiety. Overall, 79,747 (35.1%) patients filled no opioid prescription in the 12 months before OUD or overdose diagnosis, with the proportion significantly increasing between 2006 and 2016 (adjusted prevalence ratio, 1.86; 95% CI 1.79-1.93; P < 0.001). Patients without (versus with) prescribed opioids tended to be younger males and metropolitan and Northeast US residents. Of 145,609 patients who filled opioid prescriptions, 5 distinct prescribed daily dose trajectories preceding diagnosis emerged: consistent low dose (<3 mg MED, 34.6%), consistent moderate dose (20 mg MED, 27.3%), consistent high dose (150 mg MED, 15.0%), escalating dose (from <3 to 20 mg MED, 13.7%), and de-escalating dose (from 20 to <3mg MED, 9.4%). Overall, over two-thirds of patients with OUD or overdose with prescription opioids were prescribed a mean daily dose below 90 mg MED before diagnosis. Major limitations include the limited generalizability of the study findings and lack of information on out-of-pocket drug spending, race/ethnicity, and socioeconomic status of participants, which prevents analyses addressing these characteristics.
In this study, we found that absence of opioid prescription fills in the year before incident OUD or overdose diagnosis was prevalent, and the majority of the patients received prescription opioid doses below the risk threshold of 90 mg MED. An increasing proportion of high-risk patients could be missed by current programs solely based on opioid prescribing and dispensing information in this new era of limited access to prescription opioids.
随着各国政府加大力度遏制阿片类药物处方的使用,并将每日剂量控制在疾病控制与预防中心(CDC)建议的 90 毫克吗啡当量以下,人们对阿片类药物使用障碍(OUD)或过量之前的处方阿片类药物模式知之甚少。本研究旨在使用 2005-2016 年商业医疗保健数据库,确定在出现 OUD 或过量诊断之前一年内的处方阿片类药物填充和剂量轨迹。
本横断面研究在美国确定了出现 OUD 或过量的 18 至 64 岁成年人。我们测量了在诊断前 12 个月内开出的阿片类药物处方填充和阿片类药物吗啡当量(MED)剂量轨迹。在 227038 名出现 OUD 或过量的成年人中,33.1%的人年龄在 18 至 30 岁之间,52.9%的人是男性,85.0%的人居住在大都市。一半(50.5%)的患者有慢性疼痛诊断,32.7%有抑郁,20.3%有焦虑。总体而言,79747(35.1%)名患者在 OUD 或过量诊断前 12 个月内没有开出阿片类药物处方,这一比例在 2006 年至 2016 年间显著增加(调整后患病率比,1.86;95%置信区间 1.79-1.93;P<0.001)。没有(与有)开阿片类药物处方的患者往往是年轻的男性和大都市和美国东北部的居民。在 145609 名开出阿片类药物处方的患者中,出现了 5 种不同的处方日剂量轨迹:持续低剂量(<3mg MED,34.6%)、持续中等剂量(20mg MED,27.3%)、持续高剂量(150mg MED,15.0%)、剂量递增(从<3 至 20mg MED,13.7%)和剂量递减(从 20 至<3mg MED,9.4%)。总体而言,超过三分之二的 OUD 或过量处方阿片类药物的患者在诊断前接受的平均日剂量低于 90mg MED。主要限制包括研究结果的普遍适用性有限,以及缺乏参与者自付药物支出、种族/民族和社会经济地位的信息,这使得无法根据这些特征进行分析。
在这项研究中,我们发现,在出现 OUD 或过量诊断前一年没有开出阿片类药物处方的情况很普遍,而且大多数患者接受的处方阿片类药物剂量低于 90mg MED 的风险阈值。在当前这个处方阿片类药物获取受限的新时代,仅基于阿片类药物的开具和配药信息,可能会错过很大一部分高风险患者。